Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Int J Pharm ; 622: 121841, 2022 Jun 25.
Article in English | MEDLINE | ID: mdl-35623486

ABSTRACT

Several antithrombotic drugs are available to treat cardiovascular diseases due to its high mortality and morbidity worldwide. Despite these, severe adverse effects that can lead to treatment withdrawal have been described, highlighting the importance of new therapies. Thus, this work describes the development of fucoidan microparticles containing acetylsalicylic acid (MP/F4M) for pulmonary delivery and in vitro, ex vivo, and in vivo evaluation. Microparticles were prepared via spray-drying and characterized in vitro (mucoadhesive properties, coagulation time, platelet aggregation, adhesion, and hemolysis) followed by ex vivo platelet aggregation, in vivo arterial thrombosis, and hemorrhagic profile. The formulation physicochemical characterization showed suitable characteristics along with delayed drug release, increased breathable particle fraction, and high washability resistance as well as antiplatelet activity and enhanced platelet adhesion in vitro. In in vivo assays, MP/F4M protected against arterial thrombosis, without changes in the hemorrhagic profile. Finally, no lung changes were observed after prolonged pulmonary administration, whereas isolated ASA led to an inflammatory response. In conclusion, pulmonary administration of fucoidan microparticles with an antiplatelet drug may be an alternative therapy to treat cardiovascular diseases, opening the field for different formulations.


Subject(s)
Cardiovascular Diseases , Thrombosis , Aspirin , Humans , Platelet Aggregation Inhibitors/pharmacology , Polysaccharides , Thrombosis/drug therapy
2.
An Acad Bras Cienc ; 92(4): e20200834, 2020.
Article in English | MEDLINE | ID: mdl-32844987

ABSTRACT

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 213 countries in a matter of weeks. In this context, several studies correlating hemostatic disorders with the infection dynamics of the new coronavirus have emerged. These studies have shown that a portion of the patients affected by Coronavirus Disease 2019 (COVID-19) have prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), elevated D-dimer levels and other fibrinolytic products, antithrombin (AT) activity reduced and decrease of platelet count. Based on these hallmarks, this review proposes to present possible pathophysiological mechanisms involved in the hemostatic changes observed in the pathological progression of COVID-19. In this analysis, it is pointed the relationship between the downregulation of angiotensin-converting enzyme 2 (ACE2) and storm cytokines action with the onset of hypercoagulability state, other than the clinical events involved in thrombocytopenia and hyperfibrinolysis progression.


Subject(s)
Coronavirus Infections/blood , Hemostatics , Pneumonia, Viral/blood , Betacoronavirus , COVID-19 , Fibrin Fibrinogen Degradation Products/analysis , Humans , Pandemics , Partial Thromboplastin Time , Prothrombin Time , SARS-CoV-2
3.
Future Med Chem ; 10(5): 527-540, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29424562

ABSTRACT

AIM: Cancer has emerged as a growing public health problem in many parts of the world. METHODOLOGY: We describe the synthesis of a series of carbohydrate-based isoquinoline-5,8-diones through the 1,4-addition reaction between 5,8-dioxo-5,8-dihydroisoquinoline and aminocarbohydrates. Halogenated quinones were also synthesized. Their inhibitory effects on the proliferation of human cancer cell lines were studied. RESULTS & CONCLUSION: The most promising compound, derived from isoquinoline-5,8-dione, containing ribofuranosidyl ring, was selectively active in vitro against H1299 cancer cells, with 1.7-fold higher activity than that of vinorelbine tartrate. This result suggests that the glycoconjugate in question may constitute a valuable lead compound to design and synthesize a more active and less toxic derivative with respect to the development of a new antitumor substance.


Subject(s)
Antineoplastic Agents/pharmacology , Carbohydrates/pharmacology , Isoquinolines/pharmacology , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Carbohydrates/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Chlorocebus aethiops , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Isoquinolines/chemistry , Molecular Structure , Structure-Activity Relationship , Vero Cells
4.
Med Chem ; 14(3): 304-310, 2018.
Article in English | MEDLINE | ID: mdl-28676004

ABSTRACT

BACKGROUND: Over the last few years, fungal infections have emerged as a worrisome global public health problem. Candidiasis is a disease caused by Candida species and has been a problem worldwide mainly for immunosuppressed patients. Lately, the resistant strains and side effects have been reported as important issues for treating Candidiasis, which have to be solved by identifying new drugs. OBJECTIVE: The goal of this work was to synthesize a series of 1,3-benzoxathiol-2-one derivatives, XYbenzo[ d][1,3]oxathiol-2-ones, and evaluate their antifungal activity against five Candida species. METHODS: In vitro antifungal screening test and minimum inhibitory concentration determination were performed according to CLSI protocols using ketoconazole as the reference drug. The cytotoxicity of the most active compounds was evaluated by hemolysis and MTT (Vero cells) assays. RESULTS: Compounds 2 (XY = 6-hydroxy-5-nitro, MIC = 4-32 µg/mL) and 7 (XY = 6-acetoxy-5-nitro, MIC =16-64 µg/mL) showed good results when compared with current antifungals in CLSI values (MIC = 0.04-250 µg/mL). These compounds exhibited a safer cytotoxicity as well as a lower hemolytic profile than ketoconazole. CONCLUSION: Overall, the in vitro results pointed to the potential of compounds 2 and 7 as new antifungal prototypes to be further explored.


Subject(s)
Antifungal Agents/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Lactones/pharmacology , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Antifungal Agents/toxicity , Candida/drug effects , Crystallography, X-Ray , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/chemistry , Heterocyclic Compounds, 2-Ring/toxicity , Lactones/chemical synthesis , Lactones/chemistry , Lactones/toxicity , Microbial Sensitivity Tests , Molecular Structure
5.
Eur J Med Chem ; 135: 213-229, 2017 Jul 28.
Article in English | MEDLINE | ID: mdl-28453995

ABSTRACT

Cardiovascular diseases (CVDs) account for over 17 million deaths globally each year, with atherosclerosis as the underlying cause of most CVDs. Herein we describe the synthesis and in vitro mechanistic evaluation of novel N'-benzylidene-carbohydrazide-1H-pyrazolo[3,4-b]pyridines (3-22) designed as non-anionic antiplatelet agents and presenting a 30-fold increase in potency compared to aspirin. The mechanism underlying their antiplatelet activity was elucidated by eliminating potential targets through a series of in vitro assays including light transmission aggregometry, clot retraction, and quantitative ELISA, further identifying the reduction in biosynthesis of thromboxane B2 as their main mechanism of action. The intrinsic fluorescence of the compounds permits their binding to platelet membranes to be readily monitored. In silico structure-activity relationship, molecular docking and dynamics studies support the biological profile of the series revealing the molecular basis of their activity and their potential as future molecular therapeutic agents.


Subject(s)
Benzylidene Compounds/pharmacology , Blood Platelets/drug effects , Hydrazines/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Pyrazoles/pharmacology , Pyridines/pharmacology , Benzylidene Compounds/chemistry , Dose-Response Relationship, Drug , Humans , Hydrazines/chemistry , Molecular Docking Simulation , Molecular Structure , Platelet Aggregation Inhibitors/chemical synthesis , Platelet Aggregation Inhibitors/chemistry , Pyrazoles/chemistry , Pyridines/chemistry , Structure-Activity Relationship
6.
Curr Pharm Biotechnol ; 15(7): 620-8, 2014.
Article in English | MEDLINE | ID: mdl-25219867

ABSTRACT

The treatment of Diabetes Mellitus (DM), a chronic disease, is primarily based upon administration of insulin forms to patients. Conventional subcutaneous administration is associated with a large number of complications, therefore, several new strategies have been developed. Amongst these strategies, oral insulin administration is much less invasive and, therefore, well tolerated. In recent years, various nanoformulations were developed for the oral administration of insulin, allowing more effective stabilization of the active pharmaceutical ingredient and modified for better absorption along the gastrointestinal tract. The development of different oral insulin nanoformulations in academic research as well as in patents, including the development of nanoparticles, liposomes, nanoemulsions and the use of cyclodextrins deserves special attention. The future of oral insulin nanoformulations is dependent on strategies utilizing simple technologies that stabilize the raw material, including inclusion within cyclodextrins or inclusion in low weight molecular mass polymers/ oligomers. All of the theories developed here provide a solid foundation upon which to develop new methods for the production of pharmaceutical peptide formulations. In addition, the effective search for existing nanometric formulations of insulin could provide economically viable therapeutic options that can consequently be produced on an industrial scale.


Subject(s)
Diabetes Mellitus/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Nanostructures/administration & dosage , Administration, Oral , Drug Delivery Systems , Humans
7.
Curr Microbiol ; 69(3): 357-64, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24807624

ABSTRACT

Bacterial multiresistance is a health problem worldwide that demands new antimicrobials for treating bacterial-related infections. In this study, we evaluated the antimicrobial activity and the theoretical toxicology profile of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazide derivatives against gram-positive and gram-negative bacteria clinical strains. On that purpose we determined the minimum inhibitory (MIC) and bactericidal (MBC) concentrations, the in vitro cytotoxicity, and in silico risk profiles, also comparing with antimicrobial agents of clinical use. Among the 16 derivatives analyzed, four nitrofurans (N-H-FUR-NO(2), N-Br-FUR-NO(2), N-F-FUR-NO(2), N-Cl-FUR-NO(2)) showed promising MIC and MBC values (MIC = MBC = 1-16 µg/mL). The experimental data revealed the potential of these derivatives, which were comparable to the current antimicrobials with similar bactericidal and bacteriostatic profiles. Therefore, these molecules may be feasible options to be explored for treating infections caused by multiresistant strains. Our in vitro and in silico toxicity reinforced these results as these derivatives presented low cytotoxicity against human macrophages and low theoretical risk profile for irritant and reproductive effects compared to the current antimicrobials (e.g., vancomycin and ciprofloxacin). The molecular modeling analysis also revealed positive values for their theoretical druglikeness and drugscore. The presence of a 5-nitro-2-furfur-2-yl group seems to be essential for the antimicrobial activity, which pointed these acylhydrazone derivatives as promising for designing more potent and safer compounds.


Subject(s)
Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Hydrazones/pharmacology , Bacterial Infections/microbiology , Cell Survival/drug effects , Cells, Cultured , Drug Resistance, Multiple, Bacterial , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/isolation & purification , Humans , Macrophages/drug effects , Microbial Sensitivity Tests , Microbial Viability/drug effects
8.
Bioorg Med Chem ; 19(18): 5605-11, 2011 Sep 15.
Article in English | MEDLINE | ID: mdl-21840219

ABSTRACT

Tuberculosis treatment remains a challenge that requires new antitubercular agents due to the emergence of multidrug-resistant Mycobacterium strains. This paper describes the synthesis, the antitubercular activity and the theoretical analysis of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides (8a-b, 8e-f, 8i-j and 8n-o) and new analogues (8c-d, 8g-h, 8l-m and 8p-q). These derivatives were synthesized in good yields and some of them showed a promising antitubercular profile. Interestingly the N-acylhydrazone (NAH) 8n was the most potent against the Mycobacterium tuberculosis H37Rv strain (MIC=2.5 µg/mL) similar to or better than the current drugs on the market. The theoretical structure-activity relationship study suggested that the presence of the furyl ring and the electronegative group (NO(2)) as well as low lipophilicity and small volume group at R position are important structural features for the antitubercular profile of these molecules. NMR spectra, IR spectra and elemental analyses of these substances are reported.


Subject(s)
Antitubercular Agents/chemical synthesis , Antitubercular Agents/pharmacology , Hydrazines/pharmacology , Mycobacterium tuberculosis/drug effects , Triazoles/chemistry , Antitubercular Agents/chemistry , Dose-Response Relationship, Drug , Hydrazines/chemical synthesis , Hydrazines/chemistry , Microbial Sensitivity Tests , Models, Molecular , Molecular Structure , Stereoisomerism , Structure-Activity Relationship
9.
Appl Biochem Biotechnol ; 160(8): 2355-65, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19728173

ABSTRACT

Ecotin is a bidentate, fold-specific inhibitor of mammalian serine-proteases produced by Escherichia coli. This molecule may be engineered to increase and/or change its affinity and specificity providing significant biotechnological potential. Since ecotin binds tightly to serine proteases of the trypsin fold, it may help to identify the role of these enzymes in different biological processes. In this work, we tested ecotin variants as an affinity purification reagent for identifying enzymes in samples of tumor progression and mammary gland involution. Initially, we used a commercial source of urokinase-type plasminogen activator (u-PA) that remained fully active after elution from an affinity column of the ecotin variant (M84R, M85R). We then successfully identified u-PA from more complex mixtures including lysates from a prostate cancer cell line and involuting mouse mammary glands. Interestingly, a membrane-type serine protease 1 was isolated from the Triton X-100-solubilized PC-3 cell lysates, and surprisingly, haptoglobin, a serine-protease homolog protein, was also identified in mammary gland lysates and in blood. Haptoglobin does not prevent ecotin inhibition of u-PA, but it may act as a carrier within blood when ecotin is used in vivo. Finally, this affinity purification matrix was also able to identify a thrombin-like enzyme from snake venom using an ecotin variant directed against thrombin. Overall, the ecotin variants acted as robust tools for the isolation and characterization of proteins with a trypsin fold. Thus, they may assist in the understanding of the role of these serine proteases and homologous proteins in different biological processes.


Subject(s)
Escherichia coli Proteins/metabolism , Protein Engineering/methods , Protein Folding , Protein Structure, Tertiary , Serine Proteinase Inhibitors/metabolism , Trypsin/chemistry , Amino Acid Sequence , Animals , Cells, Cultured , Escherichia coli/metabolism , Female , Humans , Male , Mice , Molecular Sequence Data , Serine Proteinase Inhibitors/chemistry , Serine Proteinase Inhibitors/genetics , Trypsin/genetics , Trypsin/metabolism , Urokinase-Type Plasminogen Activator/chemistry , Urokinase-Type Plasminogen Activator/genetics , Urokinase-Type Plasminogen Activator/metabolism
10.
Arch. Clin. Psychiatry (Impr.) ; 37(2): 66-72, 2010. ilus
Article in Portuguese | LILACS | ID: lil-550604

ABSTRACT

OBJETIVO: Revisar a estrutura e o funcionamento do sistema colinérgico central ressaltando seu papel na fisiologia e na fisiopatologia das doenças de Alzheimer e Parkinson, esquizofrenia, epilepsia e tabagismo. MÉTODO: Foi realizada uma pesquisa bibliográfica no MedLine, LILACS, PubMed e ISI, e na Biblioteca da Fundação Oswaldo Cruz, RJ, selecionando-se o período de 1914 a 2009, utilizando os descritores: "receptors", "cholinergic", "Alzheimer disease", "schizophrenia", "epilepsy" e "smoking", além de referências cruzadas dos artigos selecionados e análise adicional de referências na literatura específica do tema. RESULTADOS: Efeitos importantes da ativação de receptores colinérgicos nicotínicos e muscarínicos sobre o desenvolvimento do sistema nervoso central (SNC) têm sido descritos. A dessensibilização e a internalização dos receptores acoplados à proteína G mediadas pela ativação de proteínas cinases têm sido descritas em proliferação, diferenciação e morte celular, além de síndromes neuropsiquiátricas. CONCLUSÃO: As informações produzidas a partir de estudos do sistema de neurotransmissão colinérgica podem auxiliar no desenvolvimento de medicamentos mais específicos para o tratamento da doença de Alzheimer, esquizofrenia, epilepsia e tabagismo.


OBJECTIVES: To review articles regarding important topics about cholinergic system and its ionotropic and G-protein coupled receptors as well as their regulation, also enlightening its importance in central nervous system (CNS) development and in several neuropsychiatric conditions such as Alzheimer disease, schizophrenia, epilepsy and smoking. METHOD: Bibliographical research was completed through MedLine, LILACS, PubMed, ISI and the Fundação Oswaldo Cruz Library, RJ, specifically for 1914 to 2009, using the descritors: "receptors", "cholinergic", Alzheimer "disease", "schizophrenia", "epilepsy" and "smoking", in addition to the cross-reference of the articles selected and further analyses of bibliographical references on the theme. RESULTS: Currently literature describes important effects of nicotinic and muscarinic receptors activation on development of central nervous system (CNS). The protein G coupled receptors dessensibilization and internalization mediated by kinases have been described in proliferation, differentiation and cell death, and also in neurologic disorders. DISCUSSION: The importance of the cholinergic system and its relationship with pathologies such as Alzheimer disease, schizophrenia, epilepsy is evident. The data produced so far may help on planning medicaments more specific for these pathologies treatment.


Subject(s)
Alzheimer Disease , Epilepsy , Schizophrenia , Receptors, Cholinergic , Tobacco Use Disorder
11.
J Insect Physiol ; 55(9): 840-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19505471

ABSTRACT

Defensins are cysteine-rich peptides involved in the innate immunity of insects and many other organisms. In the present study, two novel defensin-encoding cDNAs and the respective genomic DNAs (def3 and def4) of Triatoma brasiliensis were identified and their tissue-specific and temporal expression was characterized. Both of the deduced mature peptides consisted of 43 amino acid residues and were highly similar to previously identified triatomine defensins (81.4-100%). Semi-quantitative RT-PCR data showed that def3 was constitutively expressed in the fat body and was induced in salivary glands and the small intestine at 5 and 3 days after feeding (daf), respectively. The def4 mRNA level was highly up-regulated in the stomach and fat-body tissues at 5 and 3 daf, respectively. The three-dimensional structures of these defensins were predicted using a homology modeling approach with Def-AAA, the defensin from Anopheles gambiae, as template (62-74% identity). A map of the electrostatic potential of these models revealed that, despite their similar folding patterns, mature Def2 and Def4 have a more cationic structure than is the case for Def1 and Def3. Such differences may orient the antimicrobial profile of these defensins against distinct targets in different organs of the insect.


Subject(s)
Chagas Disease/parasitology , Defensins/biosynthesis , Gene Expression Regulation , Insect Proteins/chemistry , Insect Vectors/genetics , Reduviidae/genetics , Amino Acid Sequence , Animals , Base Sequence , Insect Proteins/genetics , Insect Proteins/metabolism , Insect Vectors/chemistry , Insect Vectors/metabolism , Molecular Conformation , Molecular Sequence Data , Phylogeny , Protein Binding , Reduviidae/chemistry , Reduviidae/classification , Reduviidae/metabolism , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...